Drug companies will hike launch prices to offset losses from price-inflation rebates and Medicare price negotiation, the Congressional Budget Office told Sen. Lindsey Graham (R-SC) Thursday (Aug. 4), though inflation rebates are the main reason for higher projected launch prices. Those higher prices will primarily hurt state Medicaid programs and Medicare Part B, but eventually slower price growth would attenuate the effect of higher launch prices. Graham asked CBO how Senate Democrats’ drug pricing bill would affect launch prices for...